Best CDMO in Canada: How to Choose the Right Contract Development and Manufacturing Partner
Introduction Selecting the Best CDMO in Canada requires a thorough evaluation of several critical factors, including the exact-site scope of […]
Introduction Selecting the Best CDMO in Canada requires a thorough evaluation of several critical factors, including the exact-site scope of […]
Introduction CDMO Services in Canada bring together pharmaceutical development, Good Manufacturing Practice (GMP) manufacturing, and advanced analytical testing under a
Introduction FTIR and Raman spectroscopy for peptide secondary structure provide label-free methods for evaluating molecular conformation when far-ultraviolet circular dichroism
Introduction Nitrosamine limits apply both to individual impurities and to their cumulative total whenever two or more N-nitrosamines are detected
Introduction: A virtual biotech can reach IND clearance in about 9 months when its CMC (Chemistry, Manufacturing and Controls) strategy
Introduction Qualifying active pharmaceutical ingredient (API) vendors and contract manufacturing organizations (CMOs) requires Nitrosamine Risk Assessment Services for API Suppliers
Introduction Nitrosamine Testing for Peptide and GLP-1 drug products requires a comprehensive evaluation of synthetic-route risks, peptide-specific sample preparation, and
Nitrosamine Testing for Peptide and GLP-1 Drug Products: Specialized CRO Services Read More »
Introduction Selecting a qualified Nitrosamine Testing Laboratory in Canada requires verification of active Drug Establishment Licence (DEL) compliance, highly sensitive
Introduction Forced Degradation Studies in CMC serve as the mechanistic engine of a defensible pharmaceutical impurity control strategy, linking intrinsic
Forced Degradation Studies in CMC: Building a Robust Impurity Control Strategy Read More »
Introduction Under the harmonized ICH M10 guideline, which was adopted at Step 4 on May 24, 2022, issued by the